Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies

被引:16
作者
Tan, XiangZhou [1 ]
Wen, QiaoCheng [1 ]
Wang, Ran [1 ]
Chen, ZhiKang [1 ]
机构
[1] Cent South Univ, Colorectal & Anal Surg Dept, XiangYa Hosp, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
Chemotherapy; neutropenia; CIN; prognosis; colorectal cancer; cohort studies; FLUOROURACIL DOSE ADJUSTMENT; BODY-SURFACE AREA; CELL LUNG-CANCER; BREAST-CANCER; HEMATOLOGICAL TOXICITY; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; POOLED ANALYSIS; SURVIVAL; 5-FLUOROURACIL;
D O I
10.1080/14737140.2017.1380521
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Recently, there has been a controversial discussion about the prognostic value of chemotherapy-induced neutropenia (CIN) in colorectal cancer patients. Thus, a meta-analysis was conducted to determine the relationship between CIN and the prognosis of colorectal cancer patients.Methods: We searched the PubMed, EMBASE, and Cochrane library databases to identify studies evaluating the association between CIN and colorectal cancer prognosis. Pooled random/fixed effect models were used to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the association.Results: Eight studies were selected for the meta-analysis, for a total of 2,745 patients. There was significant improved survival among colorectal cancer patients with CIN (HR=0.62, 95% CI=0.47-0.76). However, significant heterogeneity was found (p=0.000, (2)=75.0%). Through subgroup analysis, we could greatly eliminate the heterogeneity and found that neutropenia was associated with better survival in stage IV colorectal cancer patients, no matter the HR calculated by overall survival (OS) or progression-free survival (PFS). Meanwhile, the prognostic value of neutropenia in stage II/III colorectal cancer can be found when the HR is calculated by disease-free survival (DFS). Additionally, we observed significant differences after stratification according to various tumor stages, endpoints, and the use of G-CSF.Conclusions: Our results which, based on a cohort study, indicate that CIN is associated with improved survival in patients with colorectal cancer. However, further randomized controlled trials are warranted.
引用
收藏
页码:1077 / 1085
页数:9
相关论文
共 42 条
[1]   A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities [J].
Abraham, Jean E. ;
Hiller, Louise ;
Dorling, Leila ;
Vallier, Anne-Laure ;
Dunn, Janet ;
Bowden, Sarah ;
Ingle, Susan ;
Jones, Linda ;
Hardy, Richard ;
Twelves, Christopher ;
Poole, Christopher J. ;
Pharoah, Paul D. P. ;
Caldas, Carlos ;
Earl, Helena M. .
BMC MEDICINE, 2015, 13
[2]   Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel [J].
Abraham, Jean E. ;
Guo, Qi ;
Dorling, Leila ;
Tyrer, Jonathan ;
Ingle, Susan ;
Hardy, Richard ;
Vallier, Anne-Laure ;
Hiller, Louise ;
Burns, Russell ;
Jones, Linda ;
Bowden, Sarah J. ;
Dunn, Janet A. ;
Poole, Christopher J. ;
Caldas, Carlos ;
Pharoah, Paul P. D. ;
Earl, Helena M. .
CLINICAL CANCER RESEARCH, 2014, 20 (09) :2466-2475
[3]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]   Dosage of adjuvant G-CSF (filgrastim) supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients [J].
Bergh, J ;
Wiklund, T ;
Erikstein, B ;
Fornander, T ;
Bengtsson, NO ;
Malmstrom, P ;
Kellokumpu-Lehtinen, P ;
Anker, G ;
Bennmarker, H ;
Wilking, N .
ANNALS OF ONCOLOGY, 1998, 9 (04) :403-411
[5]   Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials [J].
Bonilla, Luisa ;
Ben-Aharon, Irit ;
Vidal, Liat ;
Gafter-Gvili, Anat ;
Leibovici, Leonard ;
Stemmer, Salomon M. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (24) :1845-1854
[6]   Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study [J].
Capitain, Olivier ;
Asevoaia, Andreaa ;
Boisdron-Celle, Michele ;
Poirier, Anne-Lise ;
Morel, Alain ;
Gamelin, Erick .
CLINICAL COLORECTAL CANCER, 2012, 11 (04) :263-267
[7]   Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6-treated patients [J].
Chen, Yang ;
Wang, YanRong ;
Shi, Yan ;
Dai, GuangHai .
BMC CANCER, 2017, 17
[8]   Uncovering the roles of rare variants in common disease through whole-genome sequencing [J].
Cirulli, Elizabeth T. ;
Goldstein, David B. .
NATURE REVIEWS GENETICS, 2010, 11 (06) :415-425
[9]   Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].
Citron, ML ;
Berry, DA ;
Cirrincione, C ;
Hudis, C ;
Winer, EP ;
Gradishar, WJ ;
Davidson, NE ;
Martino, S ;
Livingston, R ;
Ingle, JN ;
Perez, EA ;
Carpenter, J ;
Hurd, D ;
Holland, JF ;
Smith, BL ;
Sartor, CI ;
Leung, EH ;
Abrams, J ;
Schilsky, RL ;
Muss, HB ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439
[10]   Population pharmacokinetics of oxaliplatin [J].
Delord, JP ;
Umlil, A ;
Guimbaud, R ;
Grégoire, N ;
Lafont, T ;
Canal, P ;
Bugat, R ;
Chatelut, E .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (02) :127-131